An Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Study identifier:137-160

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2, Randomized, Double‑Blind, Placebo‑Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Medical condition

overweight

Phase

Phase 2

Healthy volunteers

No

Study drug

pramlintide acetate

Sex

All

Actual Enrollment

184

Study type

Interventional

Age

25 Years - 60 Years

Date

Study Start Date: 01 Aug 2004
Primary Completion Date: 01 May 2005
Study Completion Date: -

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

N/A

Inclusion and exclusion criteria